Apogee Therapeutics (APGE) Total Non-Current Liabilities (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Total Non-Current Liabilities data on file, last reported at $37.3 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $37.3 million in Q1 2026; TTM through Mar 2026 was $37.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $31.2 million, down 15.94% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $37.3 million, up from $31.2 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for APGE reached as high as $41.4 million in Q3 2024 and fell as low as $2.0 million in Q4 2022.
• Historically, Total Non-Current Liabilities has averaged $25.9 million across 5 years, with a median of $28.5 million in 2024.
• Across the five-year window, Total Non-Current Liabilities jumped 722.78% in 2023 and decreased 15.94% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $2.0 million in 2022, then soared by 722.78% to $16.3 million in 2023, then soared by 127.47% to $37.1 million in 2024, then dropped by 15.94% to $31.2 million in 2025, then rose by 19.61% to $37.3 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $37.3 million in Q1 2026, $31.2 million in Q4 2025, and $39.8 million in Q3 2025.